Menu Search
Equities

Bioton SA

BIO:WSE

Bioton SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)3.38
  • Today's Change-0.02 / -0.59%
  • Shares traded4.63k
  • 1 Year change-13.55%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Bioton SA had revenues fall -22.10% from 233.16m to 181.64m, though the company grew net income 60.10% from 1.42m to 2.28m.
Gross margin33.80%
Net profit margin-3.67%
Operating margin1.02%
Return on assets-0.85%
Return on equity-1.14%
Return on investment-1.04%
More ▼

Cash flow in PLNView more

In 2023, cash reserves at Bioton SA fell by 5.46m. However, the company earned 39.63m from its operations for a Cash Flow Margin of 21.82%. In addition the company used 36.95m on investing activities and also paid 8.13m in financing cash flows.
Cash flow per share0.3002
Price/Cash flow per share11.26
Book value per share6.97
Tangible book value per share3.02
More ▼

Balance sheet in PLNView more

Bioton SA has a Debt to Total Capital ratio of 8.64%, a higher figure than the previous year's 2.47%.
Current ratio1.04
Quick ratio0.2085
Total debt/total equity0.0946
Total debt/total capital0.0864
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.